ALKS 3831 (Alkermes) Drug Overview to 2026 with Phase III Data & Trials - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: ALKS 3831" report has been added to ResearchAndMarkets.com's offering.

ALKS 3831 is an orally available, fixed-dose combination of samidorphan (ALKS 33) and olanzapine being developed by Alkermes.

Samidorphan is a novel, potent mu-opioid antagonist, while olanzapine is an atypical antipsychotic with antagonist activity at the dopamine D2 and serotonin 5-HT2A receptors. ALKS 3831 was designed to display olanzapine's high antipsychotic efficacy, while also benefitting from an improved metabolic profile.

The drug is currently in Phase III development in the US, for the treatment of schizophrenia and bipolar disorder.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. ALKS 3831: Bipolar Disorder
  4. ALKS 3831: Schizophrenia

List of Figures

Figure 1: ALKS 3831 for bipolar disorder - SWOT analysis

Figure 2: ALKS 3831 for schizophrenia - SWOT analysis

Figure 3: Drug assessment summary of ALKS 3831 for schizophrenia

Figure 4: Drug assessment summary of ALKS 3831 for schizophrenia

Figure 5: ALKS 3831 sales for schizophrenia in the US, 2017-26

List of Tables

Table 1: ALKS 3831 drug profile

Table 2: ALKS 3831 Phase III trials in bipolar disorder

Table 3: ALKS 3831 drug profile

Table 4: ALKS 3831 Phase III data in schizophrenia

Table 5: ALKS 3831 Phase III trials in schizophrenia

Table 6: ALKS 3831 sales for schizophrenia in the US ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/37ks33/alks_3831?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs , Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs , Schizophrenia Drugs